GUINAN MARK
Known title: Executive Vice President & CFOCIK: 0001505998
Associated companies
Transaction History
| DGX | ▲ Buy | Grant | 20,780 | $2.7M | 3/7/2022 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 10,475 | $1.4M | 3/7/2022 | View on chart |
| DGX | ▲ Buy | Grant | 2,251 | $0 | 2/24/2022 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 1,673 | $218K | 2/23/2022 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 694 | $90K | 2/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus
Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.